ACST Stock – (NASDAQ: ACST) is giving an update on the usage
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the use of its “at-the market” equity offering plan.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement an “at-the market” equity offering system under which Acasti may issue as well as promote from time to time its everyday shares having an aggregate offering price of up to $75 million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions reported on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 million. The ATM Shares had been marketed at prevailing market rates averaging US$1.0747 per share. No securities had been marketed in the facilities of the TSXV or, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with the services of theirs. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March five, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and often will supply the Company with additional freedom in its ongoing review process to enjoy as well as evaluate strategic options.
About Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription medications making use of OM3 greasy acids delivered both as free fatty acids as well as bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy for lowering triglycerides in clients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for people with severe HTG.
Forward Looking Statements – ACST Stock
Statements of that press release that are not statements of current or historical truth constitute “forward-looking information” to the meaning of Canadian securities laws and “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking claims include known and unknown risks, uncertainties, along with other unknown elements that can cause the particular results of Acasti to be materially different from historical success and from any later results expressed or even implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be uncertain and forward-looking. Readers are actually cautioned not to place undue reliance on these forward-looking statements, which speak only as of the day of this particular press release. Forward-looking assertions in this press release include, but aren’t limited to, statements or info about Acasti’s strategy, succeeding operations as well as its review of strategic options.
The forward looking assertions contained in this specific press release are expressly qualified in the entirety of theirs by this cautionary declaration, the “Special Note Regarding Forward-Looking Statements” section in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor aisle of Acasti’s website at www.acastipharma.com. Most forward looking statements in that press release are made as of the date of this particular press release.
ACST Stock – Acasti does not undertake to redesign some such forward looking statements whether as a direct result of information which is brand new, future events or even otherwise, except as needed by law. The forward-looking assertions contained herein are also subject typically to assumptions and risks as well as uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage